Lv5
1120 积分 2024-06-01 加入
The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease
30天前
已完结
Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists
1个月前
已完结
Gut microbiota in overweight and obesity: crosstalk with adipose tissue
1个月前
已完结
Hydrogen sulfide produced by the gut microbiota impairs host metabolism via reducing GLP-1 levels in male mice
1个月前
已完结
Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists
1个月前
已完结
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
1个月前
已完结
Lean Indian patients with non-alcoholic fatty liver disease (NAFLD) have less metabolic risk factors but similar liver disease severity as non-lean patients with NAFLD
2个月前
已完结
Role of lifestyle and glucagon‐like peptide‐1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases
2个月前
已完结
Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction‐associated steatotic liver disease: A prospective, multicentre, observational study
2个月前
已完结
The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment
2个月前
已完结
皖公网安备34019202002308
